Carlos Arteaga

Carlos Arteaga is one of the foremost experts on HER2 signaling, PI3K pathway activation, and endocrine therapy resistance in breast cancer. His laboratory discoveries have directly informed clinical strategies for treating HER2-positive and hormone receptor-positive breast cancers, including the rationale for combining PI3K inhibitors with endocrine therapy. He characterized how PI3K pathway activation through PIK3CA mutation or PTEN loss constitutes a major mechanism of resistance to both endocrine therapy and anti-HER2 therapy in breast cancer, supporting FDA approval of alpelisib plus fulvestrant. His research on acquired ESR1 mutations and HER2 cross-signaling in aromatase inhibitor-resistant luminal breast cancer has shaped understanding of the evolution of endocrine resistance and therapeutic approaches to overcome it.